Purolite teams up with CPI to evaluate its Praesto modern high flow agarose Protein A resins
September 21, 2016 – Pharmaceutical –
Purolite, Bala Cynwyd, Pa., 21 September 2016 – Purolite Life Sciences today
announced a collaboration with the Centre for Process Innovation (CPI)
to perform an evaluation study of Puroliteís Praesto modern high flow agarose-based Protein A chromatography range of resins.
Hans
Johansson, Applications Leader at Purolite Life Sciences said, ‘CPI is a
natural choice for Purolite to partner with since they have the
necessary assets and resources to support our downstream resin
innovations from their state of the art £38 million National Biologics
Manufacturing Centre’. Hans further notes, ‘We also teamed up with a
leading pharmaceutical company who backed this novel study and provided
the feed material’.
CPI is utilizing PerkinElmerís analytical
assays in its performance of this evaluation study. Nico Verlinden,
Market Segment Development Leader at PerkinElmer said, ‘We are pleased
that our technologies are being used by CPI. PerkinElmerís analytical
technologies help to measure the residual process-related impurities of
the project by using our AlphaLISA technology, and purity measurements
with our LabChip GXII analysis hardware.’
Chris
Major, Sales Director for Purolite Life Sciences said, ‘Our strategy has
been to provide Protein A resins that are designed to significantly
improve cost-efficiencies across early and late stage clinical trials.
Our clinical Protein A resin, Praesto AC, addresses PI and PII needs,
reducing costs by up to 65% and increasing facility throughput. While
Praesto AP, our production phase Protein A, has been designed for PIII
and commercial production. This novel approach together with the study
output will further allow us to demonstrate the superiority of our
agarose Protein A resins’.
Chris further adds, ‘Our customers
benefit from our 35 years of heritage in the resin industry coupled with
our quality, manufacturing and regulatory experience. The collaboration
with CPI will allow us to fast track our programme to increase
downstream process efficiencies through our range of agarose resins’.
Fergal
OíBrien, Director of Biologics at CPI said ‘We are delighted to be
collaborating with Purolite and to have PerkinElmer provide advice to us
on this project. CPIís National Biologics Manufacturing Centre, which
opened in September 2015, has been designed to support the UK biologics
industry so we are delighted to be partner of choice for this particular
project which will utilise our capabilities in downstream processing.’
